Welcome to our dedicated page for ALUMIS SEC filings (Ticker: ALMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alumis Inc. filings document material events for a Nasdaq-listed biopharmaceutical issuer, including 8-K reports on clinical data, corporate presentations, operating and financial results and capital-structure activity. The disclosures identify common stock listed under ALMS on The Nasdaq Global Select Market and note the company’s emerging growth company status.
The filing record covers envudeucitinib presentations and press releases, financial-results exhibits, common-stock offering disclosures, and shareholder voting matters from the annual meeting and proxy process. These documents frame the company’s governance, material agreements, capital structure and clinical or regulatory disclosure around its TYK2 inhibitor pipeline.
ALUMIS INC. (ALMS) director Srinivas Akkaraju, through affiliated funds, reported both purchases and sales of Alumis common stock in early September 2026, with overall net buying activity. On September 8, 2026, Samsara BioCapital, L.P. sold 48,066 shares at a weighted average of $10.5484 and purchased 273,291 shares at a weighted average of $10.6271; Samsara Opportunity Fund, L.P. sold 48,065 shares and purchased 273,290 shares at the same respective weighted average prices.
On September 4, 2026, each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P. separately purchased 220,070 shares at a weighted average price of $11.1730. A holding line shows 3,553 shares held directly. A footnote states that the September 8, 2026 sales and purchases were matchable under Section 16(b), creating short-swing profit liability, and that the reporting person agreed to disgorge the short-swing profit to Alumis, less transaction costs. Another footnote explains that prices are weighted averages over disclosed intraday price ranges, and that the reporting person disclaims beneficial ownership of fund-held shares except to the extent of his pecuniary interest. No Rule 10b5-1 trading plan is indicated.
Alumis Inc. (ALMS) reported topline results from its Phase 2b LUMUS trial of oral TYK2 inhibitor envudeucitinib in moderate-to-severe systemic lupus erythematosus. The randomized, double-blind, placebo-controlled study enrolled 408 patients across four arms and did not meet its primary BICLA endpoint or key secondary endpoints in the overall intent-to-treat population.
Alumis highlighted a prespecified IFNGS-high subgroup, which represents a majority of moderate-to-severe SLE patients, where envudeucitinib showed robust clinical responses across BICLA, SRI‑4, CLASI‑50, LLDAS, steroid reduction and joint improvement. Pharmacodynamic data showed dose‑dependent interferon‑pathway inhibition with maximal suppression at 40 mg BID. Envudeucitinib was generally well tolerated, with no new safety signals, no MACE or malignancies, and lower overall TEAE rates versus placebo. Alumis plans End‑of‑Phase 2 meetings with FDA and EMA to discuss a Phase 3 program in IFNGS‑high SLE and remains on track to submit a 2026 fourth‑quarter NDA for envudeucitinib in moderate‑to‑severe plaque psoriasis.
Latigo Biotherapeutics, Inc. common stock is reported as being beneficially owned by several Foresite Capital funds and related entities, with James B. Tananbaum reporting beneficial ownership of 9,181,328 shares, or 14.5% of the company’s 63,238,030 outstanding shares as of August 7, 2026. Fund VI reports 2,203,800 shares (3.5%), Fund V 3,562,984 shares (5.6%), and Opportunity Fund V 3,414,544 shares (5.4%), with voting and dispositive power attributed through their respective general partners and Tananbaum.
The position arises from multiple venture investments: purchases of Series A-2 and Series B preferred stock in 2022–2025 at prices of $0.89869 and $1.5729 per share, a $3,500,000 convertible promissory note, a 1-for-6.42441 reverse stock split, and automatic conversion of preferred stock and the note into common stock at the closing of Latigo’s initial public offering. In the IPO, Fund VI also bought 140,000 shares at $18.00 per share. The reporting group states that the holdings are for investment purposes but may increase, reduce, or distribute their stake based on market conditions and company performance, and they are currently subject to 180‑day lock‑up and registration-rights arrangements described in the company’s prospectus.
Alumis Inc. reported for the quarter and six months ended June 30, 2026 that it remains a clinical-stage biopharma with no product revenue and significant ongoing losses. Total revenue was $1.7 million for the quarter and $3.4 million for the first half of 2026, entirely from collaboration activities with Kaken Pharmaceutical under a license and collaboration agreement.
Operating expenses remain substantial but declined versus 2025. For the first half of 2026, research and development expenses were $166.9 million and general and administrative expenses were $42.0 million, plus a $41.8 million impairment of acquired in-process R&D related to the lonigutamab program after a strategic review. This led to a net loss of $142.2 million for the quarter and $235.3 million year to date, compared with net income in the prior-year quarter that had been driven by a large gain on bargain purchase from the ACELYRIN acquisition.
Liquidity is a key focus. As of June 30, 2026, Alumis held $63.7 million in cash and cash equivalents and $438.6 million in marketable securities, or $502.3 million in total, and stockholders’ equity of $452.2 million. A January 2026 public equity offering provided net proceeds of $323.8 million, and an at-the-market facility allows for up to $300.0 million of additional common stock issuance. The company states this cash balance should fund operations for at least 12 months, but it expects to continue to incur substantial losses and will need significant additional capital to advance its autoimmune pipeline.
Alumis Inc. reported second quarter 2026 results and clinical progress. In the ONWARD3 long-term psoriasis study, 54% of patients achieved complete skin clearance (PASI 100) at 48 weeks, supporting envudeucitinib’s potential as a differentiated oral therapy in moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application in Q4 2026 and anticipates potentially pivotal Phase 2b LUMUS topline data in systemic lupus erythematosus (SLE) in Q3 2026.
For the quarter ended June 30, 2026, Alumis generated $1.662 million in collaboration revenue and recorded a net loss of $142.2 million, compared with net income of $59.3 million a year earlier, which had included a large bargain purchase gain. Operating expenses were $150.5 million, including a $41.8 million intangible assets impairment loss. Research and development expenses were $85.3 million and general and administrative expenses were $23.4 million.
As of June 30, 2026, Alumis reported cash and cash equivalents of $63.7 million and current marketable securities of $438.6 million, with total assets of $560.6 million and stockholders’ equity of $452.2 million, providing a substantial capital base to support its TYK2-focused pipeline, including envudeucitinib and CNS-penetrant candidate A-005.
Alumis Inc. reported new long-term Phase 3 data for envudeucitinib, its oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis from the ONWARD3 long-term extension study. Among 773 patients receiving up to 48 weeks of continuous treatment, 75% achieved PASI 90 and 54% achieved PASI 100, indicating near-complete and complete skin clearance. An integrated analysis across 890 patients in the ONWARD program showed PASI 90 and PASI 100 rates of 66% and 47%, respectively, after 48 weeks of therapy.
The company states that envudeucitinib’s safety and tolerability profile remained consistent with earlier ONWARD1/2 trials and no new safety signals were observed. A total of 1,509 patients rolled over into ONWARD3 from the two core Phase 3 trials, reflecting a rollover rate above 85% from a Phase 3 program enrolling more than 1,700 patients. Alumis plans to submit a New Drug Application to the FDA for envudeucitinib in plaque psoriasis in the fourth quarter of 2026 and expects topline Phase 2b data in systemic lupus erythematosus in the third quarter of 2026.
FMR LLC filed a Schedule 13G reporting beneficial ownership of 6,769,170.01 shares of Alumis Inc common stock, representing 5.5% of the class. FMR LLC reports sole voting power over 6,767,075.00 shares and sole dispositive power over 6,769,170.01 shares, with no shared voting or dispositive power.
Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 6,769,170.01 shares but no voting power. The filing notes that one or more other persons may receive dividends or sale proceeds from these shares, but no such person has more than 5% of Alumis Inc’s outstanding common stock.
Alumis Inc. Chief Financial Officer John R. Schroer reported the sale of 3,282 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share, in multiple trades between $25.56 and $26.42. According to the disclosure, the sale was a mandatory sell-to-cover transaction to satisfy tax obligations from the vesting and settlement of restricted stock units granted on July 29, 2025, and was not a discretionary trade. After these transactions, he directly owns 24,718 shares of Alumis common stock.
Alumis Inc. Chief Legal Officer Sanam Pangali reported the sale of 1,364 shares of common stock on August 3, 2026 at a weighted average price of $26.37 per share. According to the company policy, this was a mandatory sell-to-cover transaction to satisfy tax obligations from vesting restricted stock units and did not represent a discretionary sale. After the sale, Pangali held 9,747 shares of Alumis common stock directly.
Alumis Inc. executive Roy C. Hardiman, Chief Business & Strategy Officer, reported selling 2,692 shares of Common Stock on August 3, 2026 at a weighted average price of $26.37 per share. The sale was effected under the company’s policy requiring sell-to-cover transactions to satisfy tax obligations from the vesting and settlement of restricted stock units granted on July 29, 2025 and, according to the disclosure, does not represent a discretionary sale. After this transaction, he holds 207,746 shares directly, including 1,037 shares acquired on November 20, 2025 and 3,000 shares acquired on May 20, 2026 under the 2024 Employee Stock Purchase Plan, and 6,417 shares are held indirectly by his daughter residing in his primary residence.